愛迪生氏症治療藥的全球市場 2023-2027

這份報告提供愛迪生氏症治療藥的市場規模在2023年～2027年間，預測將成長到4億4,200萬美元，在預測期間內預計將以6.93％的年複合成長率增長。本報告提供愛迪生氏症治療藥市場相關資料，整體分析，市場規模與預測，趨勢，網羅了成長促進因素·課題，再加上約25供應商的供應商分析等資訊。

同時本報告還提供當前全球市場趨勢與推動因素以及整體市場環境的最新分析。

市場成長的主要因素有特效藥的指定，醫藥品的再製劑化，有利的償付情景。

目錄

第1章 摘要整理

• 市場概要

第2章 市場形勢

• 市場生態系統

第3章 市場規模

• 市場定義
• 市場區隔分析
• 市場規模 2022
• 市場預測:2022-2027年的預測

第4章 市場規模實際成果

• 全球愛迪生氏症治療藥市場2017～2021年
• 治療市場區隔分析2017-2021
• 終端用戶市場區隔分析2017-2021
• 地區市場區隔分析2017-2021
• 國家市場區隔分析2017-2021

第5章 波特的五力分析

• 五力的摘要
• 買方議價能力
• 供給企業談判力
• 新加入廠商業者的威脅
• 替代品的威脅
• 競爭的威脅
• 市場情況

第6章 各治療法市場區隔

• 市場明細
• 各治療法比較
• 口服藥 - 市場規模與預測 2022-2027
• 非口服藥 - 市場規模與預測 2022-2027
• 各治療法的市場機會

第7章 各終端用戶市場區隔

• 市場明細
• 各終端用戶比較
• 醫院和診療所 - 市場規模與預測 2022-2027
• 診斷研究所 - 市場規模與預測 2022-2027
• 各終端用戶的市場機會

第8章 客戶形勢

• 客戶形勢概要

第9章 各地區形勢

• 各地區市場區隔
• 各地區比較
• 北美 - 市場規模與預測 2022-2027
• 歐洲 - 市場規模與預測 2022-2027
• 亞洲 - 市場規模與預測 2022-2027
• 其他地區(ROW) - 市場規模與預測 2022-2027
• 美國 - 市場規模與預測 2022-2027
• 德國 - 市場規模與預測 2022-2027
• 英國 - 市場規模與預測 2022-2027
• 日本 - 市場規模與預測 2022-2027
• 加拿大 - 市場規模與預測 2022-2027
• 各地區形勢的市場機會

第10章 促進因素，課題，及趨勢

• 推動市場要素
• 市場課題
• 推動因素與課題的影響
• 市場趨勢

第11章 業者情勢

• 概要
• 業者情勢
• 混亂狀況
• 產業的風險

第12章 供應商分析

• 交易廠商
• 供應商的市場定位
• Abbott Laboratories
• Actiza Pharmaceutical Pvt. Ltd.
• Akorn Operating Co. LLC
• Amgen Inc.
• Amneal Pharmaceuticals Inc.
• Bayer AG
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Merck and Co. Inc.
• Neurocrine Biosciences Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.

第13章 附錄

Technavio has been monitoring Addison's disease therapeutics market and is poised to grow by $442 mn from 2023-2027, accelerating at a CAGR of 6.93% during the forecast period. Our report on Addison's disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by special drug designations, reformulation of drugs, and favorable reimbursement scenarios.

Technavio's Addison's disease therapeutics market is segmented as below:

By Therapy

• Oral drugs
• Parenteral drugs

By End-user

• Hospitals
• clinics
• Diagnostic laboratories

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the expanding research into the development of regenerative therapy as one of the prime reasons driving Addison's disease therapeutics market growth during the next few years. Also, the availability of clinical guidelines and redefined pathophysiology will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on Addison's disease therapeutics market covers the following areas:

• Addison's disease therapeutics market sizing
• Addison's disease therapeutics market forecast
• Addison's disease therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Addison's disease therapeutics market vendors that include Actiza Pharmaceutical Pvt. Ltd., Akorn Operating Co. LLC, Amneal Pharmaceuticals Inc., Bristol Myers Squibb Co., Neurocrine Biosciences Inc., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., GlaxoSmithKline Plc, Abbott Laboratories, Amgen Inc., Eli Lilly and Co., Biogen Inc., Boehringer Ingelheim International GmbH, Bio Techne Corp., Lupin Ltd., BTL Biotechno Labs Pvt. Ltd., and Bayer AG. Also, Addison's disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market through the study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Therapy
• Exhibit 06: Executive Summary - Chart on Market Segmentation by End-user
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global addisons disease therapeutics market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on Global addisons disease therapeutics market 2017 - 2021 ($ million)
• 4.2 Therapy Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
• 4.3 End-user Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - End-user Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy

• 6.1 Market segments
• Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)
• 6.2 Comparison by Therapy
• Exhibit 32: Chart on Comparison by Therapy
• Exhibit 33: Data Table on Comparison by Therapy
• 6.3 Oral drugs - Market size and forecast 2022-2027
• Exhibit 34: Chart on Oral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oral drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oral drugs - Year-over-year growth 2022-2027 (%)
• 6.4 Parenteral drugs - Market size and forecast 2022-2027
• Exhibit 38: Chart on Parenteral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Parenteral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Parenteral drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Parenteral drugs - Year-over-year growth 2022-2027 (%)
• 6.5 Market opportunity by Therapy
• Exhibit 42: Market opportunity by Therapy ($ million)

7 Market Segmentation by End-user

• 7.1 Market segments
• Exhibit 43: Chart on End-user - Market share 2022-2027 (%)
• Exhibit 44: Data Table on End-user - Market share 2022-2027 (%)
• 7.2 Comparison by End-user
• Exhibit 45: Chart on Comparison by End-user
• Exhibit 46: Data Table on Comparison by End-user
• 7.3 Hospitals and clinics - Market size and forecast 2022-2027
• Exhibit 47: Chart on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Data Table on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
• Exhibit 49: Chart on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
• Exhibit 50: Data Table on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
• 7.4 Diagnostic laboratories - Market size and forecast 2022-2027
• Exhibit 51: Chart on Diagnostic laboratories - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Data Table on Diagnostic laboratories - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Chart on Diagnostic laboratories - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on Diagnostic laboratories - Year-over-year growth 2022-2027 (%)
• 7.5 Market opportunity by End-user
• Exhibit 55: Market opportunity by End-user ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 57: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibit 58: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 59: Chart on Geographic comparison
• Exhibit 60: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 81: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.10 Japan - Market size and forecast 2022-2027
• Exhibit 89: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• 9.11 Canada - Market size and forecast 2022-2027
• Exhibit 93: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 97: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 98: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 99: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 100: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 101: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 102: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 103: Matrix on vendor position and classification
• 12.3 Abbott Laboratories
• Exhibit 104: Abbott Laboratories - Overview
• Exhibit 105: Abbott Laboratories - Business segments
• Exhibit 106: Abbott Laboratories - Key news
• Exhibit 107: Abbott Laboratories - Key offerings
• Exhibit 108: Abbott Laboratories - Segment focus
• 12.4 Actiza Pharmaceutical Pvt. Ltd.
• Exhibit 109: Actiza Pharmaceutical Pvt. Ltd. - Overview
• Exhibit 110: Actiza Pharmaceutical Pvt. Ltd. - Product / Service
• Exhibit 111: Actiza Pharmaceutical Pvt. Ltd. - Key offerings
• 12.5 Akorn Operating Co. LLC
• Exhibit 112: Akorn Operating Co. LLC - Overview
• Exhibit 113: Akorn Operating Co. LLC - Product / Service
• Exhibit 114: Akorn Operating Co. LLC - Key offerings
• 12.6 Amgen Inc.
• Exhibit 115: Amgen Inc. - Overview
• Exhibit 116: Amgen Inc. - Product / Service
• Exhibit 117: Amgen Inc. - Key offerings
• 12.7 Amneal Pharmaceuticals Inc.
• Exhibit 118: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 119: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 120: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 121: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 122: Amneal Pharmaceuticals Inc. - Segment focus
• 12.8 Bayer AG
• Exhibit 123: Bayer AG - Overview
• Exhibit 124: Bayer AG - Business segments
• Exhibit 125: Bayer AG - Key offerings
• Exhibit 126: Bayer AG - Segment focus
• 12.9 Bristol Myers Squibb Co.
• Exhibit 127: Bristol Myers Squibb Co. - Overview
• Exhibit 128: Bristol Myers Squibb Co. - Product / Service
• Exhibit 129: Bristol Myers Squibb Co. - Key offerings
• 12.10 Eli Lilly and Co.
• Exhibit 130: Eli Lilly and Co. - Overview
• Exhibit 131: Eli Lilly and Co. - Product / Service
• Exhibit 132: Eli Lilly and Co. - Key offerings
• 12.11 GlaxoSmithKline Plc
• Exhibit 133: GlaxoSmithKline Plc - Overview
• Exhibit 134: GlaxoSmithKline Plc - Business segments
• Exhibit 135: GlaxoSmithKline Plc - Key offerings
• Exhibit 136: GlaxoSmithKline Plc - Segment focus
• 12.12 Hikma Pharmaceuticals Plc
• Exhibit 137: Hikma Pharmaceuticals Plc - Overview
• Exhibit 138: Hikma Pharmaceuticals Plc - Business segments
• Exhibit 139: Hikma Pharmaceuticals Plc - Key offerings
• Exhibit 140: Hikma Pharmaceuticals Plc - Segment focus
• 12.13 Merck and Co. Inc.
• Exhibit 141: Merck and Co. Inc. - Overview
• Exhibit 142: Merck and Co. Inc. - Business segments
• Exhibit 143: Merck and Co. Inc. - Key news
• Exhibit 144: Merck and Co. Inc. - Key offerings
• Exhibit 145: Merck and Co. Inc. - Segment focus
• 12.14 Neurocrine Biosciences Inc.
• Exhibit 146: Neurocrine Biosciences Inc. - Overview
• Exhibit 147: Neurocrine Biosciences Inc. - Product / Service
• Exhibit 148: Neurocrine Biosciences Inc. - Key offerings
• 12.15 Novartis AG
• Exhibit 149: Novartis AG - Overview
• Exhibit 150: Novartis AG - Business segments
• Exhibit 151: Novartis AG - Key offerings
• Exhibit 152: Novartis AG - Segment focus
• 12.16 Pfizer Inc.
• Exhibit 153: Pfizer Inc. - Overview
• Exhibit 154: Pfizer Inc. - Product / Service
• Exhibit 155: Pfizer Inc. - Key news
• Exhibit 156: Pfizer Inc. - Key offerings
• 12.17 Takeda Pharmaceutical Co. Ltd.
• Exhibit 157: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 158: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 159: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 160: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 161: Inclusions checklist
• Exhibit 162: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 163: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 164: Research methodology
• Exhibit 165: Validation techniques employed for market sizing
• Exhibit 166: Information sources
• 13.5 List of abbreviations
• Exhibit 167: List of abbreviations

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Therapy
• Exhibits6: Executive Summary - Chart on Market Segmentation by End-user
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on Global addisons disease therapeutics market 2017 - 2021 ($ million)
• Exhibits19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
• Exhibits20: Historic Market Size - End-user Segment 2017 - 2021 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Therapy - Market share 2022-2027 (%)
• Exhibits31: Data Table on Therapy - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Therapy
• Exhibits33: Data Table on Comparison by Therapy
• Exhibits34: Chart on Oral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits35: Data Table on Oral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits36: Chart on Oral drugs - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on Oral drugs - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Parenteral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits39: Data Table on Parenteral drugs - Market size and forecast 2022-2027 ($ million)
• Exhibits40: Chart on Parenteral drugs - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Parenteral drugs - Year-over-year growth 2022-2027 (%)
• Exhibits42: Market opportunity by Therapy ($ million)
• Exhibits43: Chart on End-user - Market share 2022-2027 (%)
• Exhibits44: Data Table on End-user - Market share 2022-2027 (%)
• Exhibits45: Chart on Comparison by End-user
• Exhibits46: Data Table on Comparison by End-user
• Exhibits47: Chart on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
• Exhibits48: Data Table on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
• Exhibits49: Chart on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
• Exhibits50: Data Table on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
• Exhibits51: Chart on Diagnostic laboratories - Market size and forecast 2022-2027 ($ million)
• Exhibits52: Data Table on Diagnostic laboratories - Market size and forecast 2022-2027 ($ million)
• Exhibits53: Chart on Diagnostic laboratories - Year-over-year growth 2022-2027 (%)
• Exhibits54: Data Table on Diagnostic laboratories - Year-over-year growth 2022-2027 (%)
• Exhibits55: Market opportunity by End-user ($ million)
• Exhibits56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits57: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits58: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits59: Chart on Geographic comparison
• Exhibits60: Data Table on Geographic comparison
• Exhibits61: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits62: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits63: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits64: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits65: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits66: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits67: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits68: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits71: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits72: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits77: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibits78: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibits79: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits80: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits81: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits82: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits83: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits84: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits85: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits87: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibits88: Data Table on UK - Year-over-year growth 2022-2027 (%)
• Exhibits89: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits90: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits91: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits92: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits93: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits94: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits95: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits96: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits97: Market opportunity By Geographical Landscape ($ million)
• Exhibits98: Impact of drivers and challenges in 2022 and 2027
• Exhibits99: Overview on Criticality of inputs and Factors of differentiation
• Exhibits100: Overview on factors of disruption
• Exhibits101: Impact of key risks on business
• Exhibits102: Vendors covered
• Exhibits103: Matrix on vendor position and classification
• Exhibits104: Abbott Laboratories - Overview
• Exhibits105: Abbott Laboratories - Business segments
• Exhibits106: Abbott Laboratories - Key news
• Exhibits107: Abbott Laboratories - Key offerings
• Exhibits108: Abbott Laboratories - Segment focus
• Exhibits109: Actiza Pharmaceutical Pvt. Ltd. - Overview
• Exhibits110: Actiza Pharmaceutical Pvt. Ltd. - Product / Service
• Exhibits111: Actiza Pharmaceutical Pvt. Ltd. - Key offerings
• Exhibits112: Akorn Operating Co. LLC - Overview
• Exhibits113: Akorn Operating Co. LLC - Product / Service
• Exhibits114: Akorn Operating Co. LLC - Key offerings
• Exhibits115: Amgen Inc. - Overview
• Exhibits116: Amgen Inc. - Product / Service
• Exhibits117: Amgen Inc. - Key offerings
• Exhibits118: Amneal Pharmaceuticals Inc. - Overview
• Exhibits119: Amneal Pharmaceuticals Inc. - Business segments
• Exhibits120: Amneal Pharmaceuticals Inc. - Key news
• Exhibits121: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibits122: Amneal Pharmaceuticals Inc. - Segment focus
• Exhibits123: Bayer AG - Overview
• Exhibits124: Bayer AG - Business segments
• Exhibits125: Bayer AG - Key offerings
• Exhibits126: Bayer AG - Segment focus
• Exhibits127: Bristol Myers Squibb Co. - Overview
• Exhibits128: Bristol Myers Squibb Co. - Product / Service
• Exhibits129: Bristol Myers Squibb Co. - Key offerings
• Exhibits130: Eli Lilly and Co. - Overview
• Exhibits131: Eli Lilly and Co. - Product / Service
• Exhibits132: Eli Lilly and Co. - Key offerings
• Exhibits133: GlaxoSmithKline Plc - Overview
• Exhibits134: GlaxoSmithKline Plc - Business segments
• Exhibits135: GlaxoSmithKline Plc - Key offerings
• Exhibits136: GlaxoSmithKline Plc - Segment focus
• Exhibits137: Hikma Pharmaceuticals Plc - Overview
• Exhibits138: Hikma Pharmaceuticals Plc - Business segments
• Exhibits139: Hikma Pharmaceuticals Plc - Key offerings
• Exhibits140: Hikma Pharmaceuticals Plc - Segment focus
• Exhibits141: Merck and Co. Inc. - Overview
• Exhibits142: Merck and Co. Inc. - Business segments
• Exhibits143: Merck and Co. Inc. - Key news
• Exhibits144: Merck and Co. Inc. - Key offerings
• Exhibits145: Merck and Co. Inc. - Segment focus
• Exhibits146: Neurocrine Biosciences Inc. - Overview
• Exhibits147: Neurocrine Biosciences Inc. - Product / Service
• Exhibits148: Neurocrine Biosciences Inc. - Key offerings
• Exhibits149: Novartis AG - Overview
• Exhibits150: Novartis AG - Business segments
• Exhibits151: Novartis AG - Key offerings
• Exhibits152: Novartis AG - Segment focus
• Exhibits153: Pfizer Inc. - Overview
• Exhibits154: Pfizer Inc. - Product / Service
• Exhibits155: Pfizer Inc. - Key news
• Exhibits156: Pfizer Inc. - Key offerings
• Exhibits157: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibits158: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibits159: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibits160: Takeda Pharmaceutical Co. Ltd. - Key offerings
• Exhibits161: Inclusions checklist
• Exhibits162: Exclusions checklist
• Exhibits163: Currency conversion rates for US$
• Exhibits164: Research methodology
• Exhibits165: Validation techniques employed for market sizing
• Exhibits166: Information sources
• Exhibits167: List of abbreviations